NCT03809351View on ClinicalTrials.gov

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

PHASE1RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

July 8, 2026

Study Completion Date

July 8, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

[F-18]AV-1451-PET

All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.

Trial Locations (1)

35233

RECRUITING

UAB, Birmingham

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Alabama at Birmingham

OTHER